Zuojin Pill Alleviates Precancerous Lesions of Gastric Cancer by Modulating the MEK/ERK/c-Myc Pathway: An Integrated Approach of Network Pharmacology, Molecular Dynamics Simulation, and Experimental Validation
ZJP can reverse MNNG-induced PLGC, potentially through inhibition of the MEK/ERK/c-myc pathway and regulation of cellular proliferation and apoptosis.
Authors
- Jia Liu (ORCID: https://orcid.org/0000-0001-5514-9660)
- Yami Zhang
- Liuhong Yang
- Chenming He (ORCID: https://orcid.org/0000-0002-7331-8859)
- Xue Han (ORCID: https://orcid.org/0000-0001-5016-2356)
- Fengjiao Chang (ORCID: https://orcid.org/0009-0001-1780-684X)
- Jie Lin (ORCID: https://orcid.org/0000-0003-0338-6861)
- Lan Liang (ORCID: https://orcid.org/0009-0006-1004-5714)
Institutions
- Shanxi Medical University (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Longhua Hospital Shanghai University of Traditional Chinese Medicine (CN)
- Affiliated Hospital of Shaanxi University of Chinese Medicine (CN)
- Shaanxi Polytechnic University (CN)
- Xijing Hospital (CN)
- Shanxi Provincial People’s Hospital (CN)
- Shaanxi University of Chinese Medicine (CN)
- Air Force Medical University (CN)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2024-12-01
- DOI
- https://doi.org/10.2147/dddt.s487371
- Citations
- 8
- Primary Topic
- Genomics, phytochemicals, and oxidative stress
- Type
- article
- Field-Weighted Citation Impact
- 1.87